Immunotherapy of colorectal cancer-basic research

2020 is really a special year. Originally thought to be a lively Chinese New Year, it changed everything because of a menacing virus. The new coronary pneumonia makes people awaken the importance of health… In the field of colorectal cancer, American clinical tumors The KEYNOTE-177 study at the annual meeting of the Society (ASCO) is a breakthrough of the routine, with gratifying results… Previously, a basic article on immunotherapy was published in the public account. Let me talk about the results of this key research today… …Progress in immunotherapy of colorectal cancer: &nbsp.&nbsp. The KEYNOTE-177 study presented as LBA4 at the Plenary session of the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) proved that Pembrolizumab compared to standard chemotherapy ± target To treat first-line treatment of microsatellite highly unstable type (MSI-H)/mismatch repair defect (dMMR) metastatic colorectal cancer (mCRC), the efficacy of colorectal cancer immunotherapy has brought new breakthroughs and is expected to change Rewrite guidelines and norms in the field of treatment. Study details: KEYNOTE-177 study, in the first-line treatment of MSI-HmCRC patients, head-to-head comparison of Pembrolizumab and the standard treatment selected by the investigator (mFOLFOX6 or FOLFIRI chemotherapy ± targeted bevacizumab or cetuximab )Efficacy. In the treatment group chosen by the investigators, less than 20% of patients received chemotherapy, about 70% of patients received chemotherapy combined with bevacizumab, and 10% of patients received chemotherapy combined with cetuximab. The Pembrolizumab treatment group significantly prolonged the patient’s median progression-free survival (mPFS, 16.5 months to 8.2 months, HR 0.60, 95% CI 0.45-0.80, P = 0.0002). The mPFS was The latter is twice. The objective response rate (ORR) data showed that the pabolizumab treatment group was 43.8%, which was significantly higher than the researcher’s choice of the treatment group 33.1%. I believe that the US NCCN colorectal cancer guidelines will be updated soon, and China’s CSCO guidelines should also be changed. We will expect the guidelines to bring us new basis and bring new gratifying results for this part of the income group…Now can consult Specialist, my friend in Yunnan can consult me ​​if I need advice, I wish you health!